H.C. Wainwright lowered the firm’s price target on Savara (SVRA) to $6 from $10 and keeps a Buy rating on the shares. The firm questions if Savara will be able to reach its goal of identifying 1,000 patients by the Molbreevi launch.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA: